Skip to main content
Premium Trial:

Request an Annual Quote

Ncardia, Evotec Sign Licencing Agreement for iPS Cell Disease Modeling

NEW YORK (GenomeWeb) – Ncardia said today that it has entered into a non-exclusive global intellectual property licensing agreement with Evotec, which gives Evotec access to patented technology and methods for stem cell-derived modeling for target discovery, drug efficacy, and safety testing.

Ncardia has developed a variety of predictive human cellular assays systems, including a broad panel of induced pluripotent stem cell (iPSC)-derived lines of both cardiac cells and neurons.

Although financial terms of the deal were not disclosed, Ncardia CEO Stefan Braam said in a statement that the agreement is the second of its kind for the company in about two months, and "marks a further step in Ncardia technology strategy aimed at addressing the potential of stem cell applications in the drug discovery and development market."

Evotec further added that access to Ncardia's IP strengthens its own position as a platform for iPSC-based drug discovery.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.